Search clinical trials for: Indacaterol and tiotropium

Total 271200 results

Boehringer Ingelheim

Completed

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Austria, Belgium, Brazil, Canada, China, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Norway, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

Asthma

United States, Chile, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Russian Federation, Slovakia, Spain, Ukraine
Amgen

Completed

Juvenile Rheumatoid Arthritis

Juvenile Chronic Arthritis
Duke University

Withdrawn

Tiotropium Handihaler vs. Tiotropium Respimat in COPD

Chronic Obstructive Pulmonary Disease (COPD)
Boehringer Ingelheim

Completed

Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
University Medical Center Groningen
Novartis

Completed

Anti-inflammatory Effects Glycopyrronium

Asthma | Allergic Asthma

Netherlands
Boehringer Ingelheim

Completed

Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD

Pulmonary Disease, Chronic Obstructive

Denmark, Austria, Finland, France, Slovenia
Boehringer Ingelheim

Completed

A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD

Pulmonary Disease, Chronic Obstructive

Germany
Orion Corporation, Orion Pharma

Completed

Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler (TEMPO)

Healthy Volunteers

Finland
Celldex Therapeutics

Completed

A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer (EMERGE)

Breast Cancer

United States
Boehringer Ingelheim

Completed

Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment

Healthy
Virginia Commonwealth University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Interleukin-1 Blockade in HF With Preserved EF (D-HART2)

Heart Failure With Normal Ejection Fraction

United States
University of Utah

Completed

Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices

Heart Failure

United States
Boehringer Ingelheim

Completed

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, New Zealand, Portugal, Russian Federation, United Kingdom
Xiromed LLC
Laboratorios Liconsa; Exeltis

Completed

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARBORUS)

COPD

United States, India
Boehringer Ingelheim

Completed

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany
Boehringer Ingelheim

Completed

Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Novartis Pharmaceuticals

Completed

Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD

COPD

Germany, Spain, United Kingdom, Italy
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler® (TESSA)

Healthy Volunteers

Finland
The Korean Academy of Tuberculosis and Respiratory...
GlaxoSmithKline

Completed

Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea

Chronic Obstructive Pulmonary Disease

Korea, Republic of
Diabetes Care Center

Completed

A Comparison of Two Initial Dosing Formulas

Diabetes Mellitus, Type 2

United States
Orion Corporation, Orion Pharma

Completed

Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler (FINDA)

Healthy Volunteers

Finland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Different Doses of Indacaterol

Asthma

United States
Boehringer Ingelheim

Completed

Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects

Healthy
Novo Nordisk A/S

Completed

Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Indonesia
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Terminated

Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Italy
Federal University of São Paulo

Completed

Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients

Pulmonary Disease, Chronic Obstructive | Pulmonary Emphysema | Chronic Bronchitis

Brazil
Boehringer Ingelheim

Completed

Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice

Pulmonary Disease, Chronic Obstructive

Taiwan
Royal Free and University College Medical School
Boehringer Ingelheim

Completed

Effect of Tiotropium on Inflammation and Exacerbations in COPD

Chronic Obstructive Pulmonary Disease

United Kingdom
Novartis

Completed

Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control

Chronic Obstructive Pulmonary Disease

Russian Federation, United Kingdom, Spain, Germany, Argentina, Italy, Netherlands, Switzerland, Turkey, France, Czech Republic, Hungary, Slovakia, Peru, Korea, Republic of, Colombia, Israel, Chile, Denmark, Ecuador, Egypt, Estonia, ... and more
Novartis Pharmaceuticals

Completed

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Spain, United States, Belgium
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Germany, Denmark, Italy, Canada, Czech Republic, Hungary, India, Slovakia, France, Colombia, Finland, Taiwan, Iceland, Peru
Novartis

Completed

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, France
Boehringer Ingelheim

Completed

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Belgium, Denmark, Germany, Hungary
Boehringer Ingelheim

Completed

Tiotropium and Salmeterol PK Study in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
Boehringer Ingelheim
Pfizer

Completed

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, Spain, Turkey, Ukraine, United...
Boehringer Ingelheim

Completed

Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders

Pulmonary Disease, Chronic Obstructive

France
Novartis

Completed

Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma

Asthma

Canada
University of Milan
Fondazione Salvatore Maugeri

Completed

Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients

Hyperinflation | COPD | Right Cardiac Failure

Italy
Elpen Pharmaceutical Co. Inc.

Not yet recruiting

QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt. (TRITON)

COPD
GlaxoSmithKline

Completed

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, United States
GlaxoSmithKline

Completed

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) (AC4115321)

Pulmonary Disease, Chronic Obstructive

United States
3M

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference

Healthy
Boehringer Ingelheim

Completed

A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler

Pulmonary Disease, Chronic Obstructive

Australia, New Zealand, United Kingdom
Boehringer Ingelheim

Completed

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

Pulmonary Disease, Chronic Obstructive

United States
AstraZeneca

Terminated

A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease | COPD

Poland, Sweden
Boehringer Ingelheim

Completed

Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD

Pulmonary Disease, Chronic Obstructive

Korea, Republic of

3

Subscribe